Warrants (Details) - $ / shares |
12 Months Ended | |
|---|---|---|
Jan. 31, 2024 |
Jan. 31, 2023 |
|
| Warrants | ||
| Warrants Outstanding Shares, Beginning | 3,356,000 | 4,991,000 |
| Cancelled, Shares | (1,325,000) | (875,000) |
| Exercised, Shares | (785,000) | |
| Granted, Shares | 580,000 | 25,000 |
| Warrants Outstanding Shares, Ending | 2,611,000 | 3,356,000 |
| Warrants Outstanding Weighted Average Conversion Price, Beginning | $ 3.60 | $ 2.83 |
| Weighted Average Conversion Price, Cancelled | 1.82 | 1.71 |
| Weighted Average Conversion Price, Exercised | 1.00 | |
| Weighted Average Conversion Price, Granted | 1.00 | 9.00 |
| Warrants Outstanding Weighted Average Conversion Price, Ending | $ 1.09 | $ 3.60 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Change in the weighted average exercise price of options outstanding. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|